NCT05006534View on ClinicalTrials.gov

Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
Relapsed Non Hodgkin LymphomaRefractory Lymphoma
Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT05006534 - Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter